Mark Zipkin (@markzipkin) 's Twitter Profile
Mark Zipkin

@markzipkin

Science writer and PR EIC. All opinions expressed are my own.

ID: 2820708596

calendar_today20-09-2014 00:12:19

73 Tweet

199 Followers

92 Following

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

Evox is partnering with Lilly to deliver RNAi and antisense oligos using exosomes: biocentury.com/article/305423 Why I remember when Evox was just a wee fledgling of a biotech: biocentury.com/article/283440

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

Great coverage from @_Ktktktktk of yesterday's deal between Codiak and Sarepta Therapeutics to nestle AAVs inside of exosomes: biocentury.com/article/305516 Surprised this wasn't an ASO-exosome deal. Evox Systems Pvt. Ltd. announced one last week, and Codiak is presenting on their exoASO program @ AACR today.

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

My first BioSpace article! Oncorus Pivots to Scale Up Manufacturing with New GMP Facility biospace.com/article/oncoru… #jobs

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

The plot thickens: ​FDA Delays Decision for Biogen's Alzheimer's Drug Until June | BioSpace biospace.com/article/-fda-e… #jobs

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

COVID-19 Vaccine News: Moderna Variant Vaccine Begins Human Testing, AZ Put on Hold in Denmark biospace.com/article/covid-…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

My latest feature on exosomes: Leading Approaches to Extracellular Vesicle Therapies | BioSpace biospace.com/article/leadin…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

My first piece for Labiotech.eu! Have European Investors Missed the Exosome ‘Gold Rush’?labiotech.eu/trends-news/ex…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

My first News Feature for Nature Aging, on aducanumab and the state of the Abeta hypothesis: nature.com/articles/s4358…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

New paper from U Cambridge team shows neural stem cells use EVs to transfer mitochondria, improved clinical efficacy in mouse model of MS: plos.io/31WMLGQ EV-transfered mtDNA previously showed promise in cancer: biocentury.com/article/290875…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

My latest feature: Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens on Labiotech.eu labiotech.eu/trends-news/ne…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

One of my clients, BioSpace, is running a really interesting webinar next week looking at the biopharma workplace post-pandemic. Check it out here: marketing.biospace.com/the-future-of-…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

My latest news feature for NBT: Fecal microbiota potentiate checkpoint inhibitors, unleash microbiome startups nature.com/articles/d4158…

Mark Zipkin (@markzipkin) 's Twitter Profile Photo

Big news on aducanumab/Abeta today, but as I wrote back in April, the field has very mixed feelings: nature.com/articles/s4358…